Lactobacilli and bifidobacteria ameliorate memory and learning deficits and oxidative stress in β-amyloid (1–42) injected rats

Azm, Somayeh Athari Nik; Djazayery, A; Safa, Majid; Azami, Kian; Ahmadvand, Behzad; Sabbaghziarani, Fatemeh; Sharifzadeh, Mohammad; Vafa, Mohammadreza

doi:10.1139/apnm-2017-0648

Cited by 220 publications

(90 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…First reports indicate successful application in animal models: Lactobacillus plantarum, for example, was able to restore cognition and levels of acetylcholine esterase in the brain of a D-galactose-evoked AD-like rat model [94]. Similar results were obtained from investigations using genetic AD mouse models with Bifidobacterium breve strain A1 [95], SLAB51 (probiotic formulation, [96]) but also with Lactobacillus acidophilus, Lactobacillus fermentum, Bifidobacterium lactis, and Bifidobacterium longum in rodent sporadic AD models due to amyloid-β injection [97][98][99]. As only one explorative intervention study reports on a small cohort of AD human patients [100], the usefulness in humans is still not proven.…”

Section: Therapeutic Strategies Derived From Microbes Against Human Asupporting

confidence: 67%

Amyloidogenic Peptides in Human Neuro-Degenerative Diseases and in Microorganisms: A Sorrow Shared Is a Sorrow Halved?

Endres

2020

Molecules

View full text Add to dashboard Cite

The term “amyloid” refers to proteinaceous deposits of peptides that might be generated from larger precursor proteins e.g., by proteolysis. Common to these peptides is a stable cross-β dominated secondary structure which allows self-assembly, leading to insoluble oligomers and lastly to fibrils. These highly ordered protein aggregates have been, for a long time, mainly associated with human neurodegenerative diseases such as Alzheimer’s disease (Amyloid-β peptides). However, they also exert physiological functions such as in release of deposited hormones in human beings. In the light of the rediscovery of our microbial commensals as important companions in health and disease, the fact that microbes also possess amyloidogenic peptides is intriguing. Transmission of amyloids by iatrogenic means or by consumption of contaminated meat from diseased animals is a well-known fact. What if also our microbial commensals might drive human amyloidosis or suffer from our aggregated amyloids? Moreover, as the microbial amyloids are evolutionarily older, we might learn from these organisms how to cope with the sword of Damocles forged of endogenous, potentially toxic peptides. This review summarizes knowledge about the interplay between human amyloids involved in neurodegenerative diseases and microbial amyloids.

show abstract

Section: Therapeutic Strategies Derived From Microbes Against Human Asupporting

confidence: 67%

Amyloidogenic Peptides in Human Neuro-Degenerative Diseases and in Microorganisms: A Sorrow Shared Is a Sorrow Halved?

Endres

2020

Molecules

View full text Add to dashboard Cite

show abstract

“…The presence of a gut–brain axis modulating dementia physiopathology was first demonstrated with the circumstance that urolithins, gut microbiota-derived metabolites from grape seed ellagitannins, can improve β-amyloid aggregation and signs of cognitive impairment in animal models 80,81. Then, the administration of other prebiotics, including teasaponin, fructo-oligosaccharides, baicalein and xylo-oligosaccharides, proved effective in preventing the advancement of cognitive symptoms in mouse models of AD or vascular dementia 79,82–84…”

Section: Resultsmentioning

confidence: 99%

Gut microbiota, cognitive frailty and dementia in older individuals: a systematic review

Ticinesi¹,

Tana²,

Nouvenne³

et al. 2018

CIA

168

133

View full text Add to dashboard Cite

Cognitive frailty, defined as the coexistence of mild cognitive impairment symptoms and physical frailty phenotype in older persons, is increasingly considered the main geriatric condition predisposing to dementia. Recent studies have demonstrated that gut microbiota may be involved in frailty physiopathology by promoting chronic inflammation and anabolic resistance. The contribution of gut microbiota to the development of cognitive impairment and dementia is less defined, even though the concept of “gut–brain axis” has been well demonstrated for other neuropsychiatric disorders. The aim of this systematic review was to summarize the current state-of-the-art literature on the gut microbiota alterations associated with cognitive frailty, mild cognitive impairment and dementia and elucidate the effects of pre- or probiotic administration on cognitive symptom modulation in animal models of aging and human beings. We identified 47 papers with original data (31 from animal studies and 16 from human studies) suitable for inclusion according to our aims. We concluded that several observational and intervention studies performed in animal models of dementia (mainly Alzheimer’s disease) support the concept of a gut–brain regulation of cognitive symptoms. Modulation of vagal activity and bacterial synthesis of substances active on host neural metabolism, inflammation and amyloid deposition are the main mechanisms involved in this physiopathologic link. Conversely, there is a substantial lack of human data, both from observational and intervention studies, preventing to formulate any clinical recommendation on this topic. Gut microbiota modulation of cognitive function represents, however, a promising area of research for identifying novel preventive and treatment strategies against dementia.

show abstract

“…Probiotics are live microorganisms intended to provide health benefits, generally by improving or restoring the GM [22][23][24]49]. Moreover, Athari Nik AGING Azm et al [50] pointed out that reduction in the number of amyloid plaques, inflammation and oxidative stress were observed in an Alzheimerprobiotics group. Kobayashi et al [51] also revealed that probiotics administration suppressed hippocampal gene expression of inflammation and oxidative stress related genes in an AD mouse model.…”

Section: Discussionmentioning

confidence: 99%

Efficacy of probiotics on cognition, and biomarkers of inflammation and oxidative stress in adults with Alzheimer’s disease or mild cognitive impairment — a meta-analysis of randomized controlled trials

Den

Dong

Chen

et al. 2020

Aging

162

104

View full text Add to dashboard Cite

Probiotics are live microbes that confer health benefits to the host. Preliminary animal evidence supports the potential role of probiotics in ameliorating cognitive health, however, findings from clinical trials in Alzheimer's disease (AD) or mild cognitive impairment (MCI) subjects are controversial. Thus, a meta-analysis is needed to clarify the efficacy of probiotics on cognition in AD or MCI patients. EMBASE, PubMed, Web of Science and Cochrane library were systematically searched and manually screened for relevant published randomized controlled trials (RCTs). Among the 890 citations identified, 5 studies involving 297 subjects met eligibility. There was a significant improvement in cognition (SMD = 0.37; 95% CI, 0.14, 0.61; P = 0.002; I 2 = 24%), while a significant reduction in malondialdehyde (SMD = −0.60; 95% CI, −0.91, −0.28; P = 0.000; I 2 = 0.0%) and high-sensitivity Creactive protein (SMD = −0.57; 95% CI, −0.95, −0.20; P = 0.003; I 2 = 0.0%) post-intervention levels between the probiotics and control group. This meta-analysis indicated that probiotics improved cognitive performance in AD or MCI patients, possibly through decreasing levels of inflammatory and oxidative biomarkers. However, current evidence is insufficient, and more reliable evidence from large-scale, long-period, RCT is needed.

show abstract

Lactobacilli and bifidobacteria ameliorate memory and learning deficits and oxidative stress in β-amyloid (1–42) injected rats

Cited by 220 publications

References 43 publications

Amyloidogenic Peptides in Human Neuro-Degenerative Diseases and in Microorganisms: A Sorrow Shared Is a Sorrow Halved?

Amyloidogenic Peptides in Human Neuro-Degenerative Diseases and in Microorganisms: A Sorrow Shared Is a Sorrow Halved?

Gut microbiota, cognitive frailty and dementia in older individuals: a systematic review

Efficacy of probiotics on cognition, and biomarkers of inflammation and oxidative stress in adults with Alzheimer’s disease or mild cognitive impairment — a meta-analysis of randomized controlled trials

Contact Info

Product

Resources

About